A large investigation found that hidden blood pressure drops are common after cellular therapies, with most patients experiencing orthostatic hypotension within the first month of treatment. The study, described as one of the largest analyses of its kind, reported that more than half of treated patients develop the condition upon standing. Orthostatic hypotension can complicate recovery by raising risks of falls, dizziness, and downstream cardiovascular instability, making it a practical safety issue beyond classic immune or infectious complications. For clinical teams managing post-infusion monitoring, it reinforces the need for standardized assessment timing and intervention pathways. The next step for investigators will be identifying predictors—such as baseline autonomic function, treatment regimen, and supportive-care medications—and whether proactive management can reduce severity or duration.